Research in IMO
iPS cells as a study tool and model to implement the CRISPR-Cas system in the treatment of Retinal Dystrophies
The ultimate goal of this research is to lay the foundation for the application of cell therapy in the treatment of retinal dystrophies, by implanting healthy cells, obtained from iPS cells, in the patients' affected tissues.
A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Macular Degeneration
Influence of posterior vitreous detachment on retinal detachment after lens surgery in myopic eyes.
Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies
Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.
Open-label phase IV trial to examine the change of vision-related quality of life in subjects with diabetic macular oedema (DMO) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.